Brief: Thomas Pike To Join Labcorp As President And CEO Of Its Drug Development Clinical Development Business Unit
Jan 5 (Reuters) - Laboratory Corporation of America
Holdings LH.N :
* THOMAS PIKE TO JOIN LABCORP AS PRESIDENT AND CHIEF
EXECUTIVE
OFFICER OF ITS DRUG DEVELOPMENT CLINICAL DEVELOPMENT BUSINESS
UNIT
* LABCORP - AT TIME OF SPIN-OFF OF CLINICAL DEVELOPMENT
BUSINESS,
PIKE WILL SERVE AS CEO & CHAIRMAN OF INDEPENDENT, PUBLICLY
LISTED CO
Source text for Eikon: ID:nBw4d4rGRa
Further company coverage: LH.N
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Laboratory of America Holdings
See all newsBrief: Labcorp To Announce Second Quarter 2026 Financial Results On July 30, 2026
Brief: Labcorp And Epic Expand Collaboration To Advance Diagnostic Integration Across Hospitals And Health Systems
U.S. STOCKS ON THE MOVE-Quanta, O'Reilly Automotive, Avis
Labcorp lifts full‑year forecast as diagnostics business stays resilient (updated)
U.S. STOCKS ON THE MOVE-Qualcomm, Meta, Cardinal Health